Search Results for “biotechnology” – Page 12 – media

Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.Immunology and inflammation continues to be one of the hottest areas for research, and investment firm Blackstone is joining in with the launch of Uniquity Bio, a new startup whose lead asset from Merck addresses a clinically validated target that puts it in direct competition with some big pharmaceutical companies. Uniquity is backed by up to $300 million in financing from Blackstone Life Sciences, the firm’s biotechnology investment division. The in-licensed Merck drug, solrikitug, is ready to begin Phase 2 development in its lead indications, chronic obstructive pulmonary disease (COPD) and asthma. The Uniquity pipeline includes a third undisclosed gastrointestinal indication. Solrikitug is a monoclonal antibody designed to block thymic stromal lymphoprotein ...
- Source: drugdu
- 78
- May 17, 2024
BBSRC invests £48m in Babraham Institute to advance lifelong health research

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability to protect health and counter age-related decline, including cellular response to stress, epigenetic control across the life course, immunity, resilience and repair. In close collaboration with partners across academia, including the BBSRC’s other strategically supported research institutes and companies based on the Babraham Research Campus, the research will be delivered ...
- Source: drugdu
- 107
- May 16, 2024
Answering the Call

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients. Yvonne Greenstreet, CEO, Alnylam It’s no surprise that Yvonne Greenstreet is winning awards. On Jan. 9, the Healthcare Businesswomen’s Association (HBA) announced the Alnylam CEO as its 2024 Woman of the Year. In the release, the HBA said that Greenstreet had earned the honor through her “notable and remarkable commitment and valuable contributions to women in the healthcare ecosystem.” It went on to describe Greenstreet as a trailblazer, advocate, and a true leader. Specifically, Greenstreet’s leadership at Alnylam, an RNA interference (RNAi) therapeutics company, was recognized. Since being appointed CEO in October 2021, she has helped steer Alnylam to being named one of Fortune’s Best Workplaces for Women. ...
- Source: drugdu
- 71
- May 14, 2024
OneChain’s CAR T trial treats its first cortical T-cell ALL patient

The subtype accounts for 20% of all T-cell leukaemias, a rare form of blood cancer which produces too many abnormal T-cells OneChain Immunotherapeutics (OCI), a biotechnology company that specialises in developing CAR T cell therapies for oncological diseases, has announced that the CARxALL clinical trial has dosed its first cortical T-cell acute lymphoblastic leukaemia (coT-ALL) patient with OC-1, a CAR T therapy. Being conducted at Hospital Clínic and Hospital Sant Joan de Déu in Barcelona, the trial is open to both paediatric and adult patients worldwide. T-cell leukaemia is a rare form of blood cancer that occurs when the bone marrow produces too many abnormal T-cells, a type of white blood cell that protects the body from infections. The subtype, coT-ALL, accounts for 20% of T-cell leukaemias and is characterised by a poor prognosis in patients who do not respond to existing therapies. CAR T therapies are a form of ...
- Source: drugdu
- 117
- May 13, 2024
AstraZeneca Finalizes Equity Investment, Research Collaboration with Cellectis

Don Tracy, Associate Editor Joint venture aims to develop up to 10 new cell and gene therapy products targeting areas with high unmet medical needs. AstraZeneca announced that it has officially completed its equity investment and research collaboration agreement with Cellectis, a biotechnology company specializing in gene editing technologies. According to the company, the agreement is expected to result in a collaboration to develop up to 10 different cell and gene therapy (CGT) products in areas such as oncology, immunology, and rare diseases. Regarding terms of the deal, Cellectis earned an upfront payment of $105 million, which included $25 million in cash and $80 million in an equity investment. Cellectis will have the opportunity to profit further through an investigational new drug (IND) option fee, and additional payments based on development, regulatory, and sales milestones that could range from $70 million to $220 million.1 The collaboration, which was first announced ...
- Source: drugdu
- 105
- May 9, 2024
Novartis Set to Acquire Mariana Oncology to Enhance Radioligand Therapy Pipeline

Don Tracy, Associate Editor Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers. Novartis announced that it has acquired Mariana Oncology, a biotech specializing in developing radioligand therapies (RLTs) for cancer treatment. According to the company, the acquisition is expected to enhance Novartis’ existing RLT pipeline and add major research capabilities. These programs target breast, prostate, and lung cancers, and features a leading developmental candidate, MC-339, for small cell lung cancer. As per terms of the agreement, Novartis is expected to make an upfront payment of $1 billion, with further potential payments of up to $750 million upon the completion of pre-specified milestones.1 “The acquisition of Mariana Oncology reflects our commitment to radioligand therapy as one of our company’s key technology platforms and strengthens our leadership in this field,” said Fiona Marshall, president, biomedical research, Novartis, in a press release. “We are ...
- Source: drugdu
- 118
- May 6, 2024
BigHat Biosciences partners with Janssen Biotech

Strategic collaboration to leverage BigHat’s AI/ML (Artificial Intelligence / Machine Learning) guided Milliner platform to design high-quality next-generation protein therapeutics BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company. This strategic collaboration combines the drug discovery, clinical development and data science expertise from Johnson & Johnson with BigHat’s Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation. BigHat’s antibody design platform, Milliner, integrates a synthetic biology-based high-speed wet lab with machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. This approach reduces the difficulty of designing antibodies and other therapeutic proteins ...
- Source: drugdu
- 108
- May 5, 2024
Sino Biological concludes SignalChem acquisition for $48m.

Sino Biological has concluded the acquisition of Canadian biotechnology company SignalChem Biotech (SCB) for $48m in a move that expands its product portfolio and strengthens its global presence. The related share purchase agreement was signed between the companies in October 2023. The deal includes all assets and assumed indebtedness, along with net cash deposits, marking a significant expansion for the Shenzhen stock exchange-listed biotech company. Sino Biological president and general manager Dr Jie Zhang stated: “SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies. “The acquisition of SCB further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services.” SignalChem is engaged in developing bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. It is now integrated as a wholly-owned subsidiary of Sino Biological. SCB will offer exclusive ...
- Source: https://www.pharmaceutical-technology.com/news/sino-biological-signalchem-48m/
- 80
- May 4, 2024
Pioneer Institute study finds IRA discourages non-opioid drug innovation

Astudy from a US-based public policy research firm has highlighted that the US Inflation Reduction Act (IRA) is likely to stifle research efforts into non-opioid pain medications. The ongoing opioid crisis in the US demands alternatives to addictive pain medications. Several pharma companies have been accused of fuelling the opioid crisis by downplaying the addiction risks of their prescription pain drugs, contributing to the out-of-control opioid addiction problem in many American cities. The majority of heroin and fentanyl addictions stem from initial use of prescription drugs. According to a report on GlobalData’s Pharma Intelligence Center, there were 1,038,938 diagnosed cases of opioid use disorder in the US in 2022. This number is expected to increase to 1,062,610 in 2027. Introduced in 2022, the IRA allows Medicare to negotiate prices and rebates for certain drugs from drug makers in a pursuit to curb inflation. Critics have said the IRA may discourage ...
- Source: drugdu
- 127
- May 3, 2024
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding

On Wednesday, 3 April, 2024, a letter from the House’s Select Committee on the Chinese Communist Party recommended more companies to add to the Pentagon’s list of firms that are allegedly working with the Chinese military. The letter identifies several companies, including two headquartered in California—Innomics (Sunnyvale, CA, US) and Axbio (Santa Clara, CA, US)—as potentially Chinese military-backed companies, and implied the companies may have tried to hide their affiliation with Chinese-headquartered BGI Genomics (Shenzhen, China), which has been on the security risk list since 2022. Other Chinese companies recommended for the list are Origincell (Shanghai, China), Vazyme Biotech (Nanjing, China), and STOmics (Shenzhen, China). The letter states that Innomics recently registered to conduct business operations in Kentucky under BGI. Innomics provides sequencing services to institutional and corporate clients for research purposes and STOmics sells lab kits and reagents. BGI asserts that both Innomics and STOmics belong to BGI but ...
- Source: drugdu
- 110
- May 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.